CoChat

Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease

Open access
Sakurai, Toshiyuki, Saruta, Masayuki · 2023 · Digestion

The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.

Abstract

Background: Mucosal healing (MH) was proposed to be an ideal treatment goal for patients with inflammatory bowel disease (IBD). Instead of endoscopy to confirm MH, biomarkers are frequently used and have become an indispensable modality for the clinical examination of patients with IBD. Summary: Common biomarkers of IBD include C-reactive protein (CRP), erythrocyte sedimentation rate, antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, leucine-rich α2 glycoprotein, fecal calprotectin (FCP), and the fecal immunochemical test. Biomarkers play five major roles in the management of IBD: (1) diagnosing and distinguishing between IBD and non-IBD or ulcerative colitis and Crohn’s disease; (2) predicting treatment response, especially before administrating biologics; (3) monitoring and grasping endoscopic or histological disease activity; (4) replacing endoscopy for diagnosing MH, including endoscopic and histological remission; and (5) predicting recurrence before disease activity appears through symptoms. Many reports have demonstrated the usefulness of CRP and FCP for those five roles; however, they have limitations for diagnosing MH or predicting treatment response. In general, FCP has better ability in those positions than CRP; additionally, leucine-rich α2 glycoprotein can diagnose endoscopic disease activity better than CRP. The novel biomarker, prostaglandin E-major urinary metabolite, and anti-αvβ6 antibody are expected to be noninvasive and reliable biomarkers; however, more evidence is required for future studies. Oncostatin M and microRNA are also prospects, in addition to other familiar and novel biomarkers. Key Messages: Each biomarker has a useful feature; therefore, we should consider their features and use appropriate biomarkers for the five roles to enable noninvasive and smooth management of IBD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000527846

Cites

137 of 137 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Five positions of biomarkers in inflammatory bowel disease. There are five roles of biomarkers in the management of inflammatory bowel disease. A. Diagnosis. B. Prediction of treatment response. C. Monitoring disease activity. D. Diagnosing MH. E. Prediction of recurrence. MH, mucosal healing.
Fig. 1 Five positions of biomarkers in inflammatory bowel disease. There are five roles of biomarkers in the management of inflammatory bowel disease. A. Diagnosis. B. Prediction of treatment response. C. Monitoring disease activity. D. Diagnosing MH. E. Prediction of recurrence. MH, mucosal healing.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 137 references

Cited by

See all 156

Metadata

Authors
Sakurai, T., & Saruta, M.
Affiliations
Jikei University School of Medicine (JP)
Corresponding author
Sakurai, Toshiyuki
Venue
Digestion
Publisher
S. Karger AG
Published
2022-11-18
Volume
104
Issue
1
Pages
30-41
ISSN
  • 0012-2823 (ISSN-L)
  • 1421-9867
OpenAlex
W4309466247
Cited by
156
References
137
Citations by year
2026: 43 · 2025: 48 · 2024: 42 · 2023: 23
FWCI
4.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Digestion (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
Keywords
inflammatory bowel disease, biomarkers, mucosal healing, fecal calprotectin, C-reactive protein, LRG1, ASCA, antineutrophil cytoplasmic antibodies, fecal immunochemical test, disease activity monitoring, treatment response prediction, disease recurrence prediction, ulcerative colitis, Crohn's disease, non-invasive diagnosis, oncostatin M, microRNA
MeSH terms
C-Reactive Protein, Colitis, Ulcerative, Feces, Glycoproteins, Humans, Leucine, Severity of Illness Index, Inflammatory Bowel Diseases, Biomarkers, Leukocyte L1 Antigen Complex

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease. https://app.cochat.ai/papers/10.1159/000527846
The paper
Sakurai, T., & Saruta, M. (2023). Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease. Digestion. https://doi.org/10.1159/000527846

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.